Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

▤ Summary

Precigen shared updated long-term follow-up data for PAPZIMEOS in adults with recurrent respiratory papillomatosis. The company highlighted that 83% of complete responders remained in complete response for at least 36 months, and five patients stayed response-free beyond four years. No new safety issues appeared during follow-up, and the median duration of complete response has not yet been reached. The FDA also granted PAPZIMEOS seven-year orphan-drug market exclusivity, reinforcing its commercial position as the first and only approved therapy for adult RRP.

▦ Linked Companies